Yorktown Management & Research Company’s Takeda Pharmaceutical TAK Stock Holding History

Yorktown Management & Research Company’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,000	Closed	-$264K	–	211
2023 Q1	$264K	Buy	+16,000	New	+$255K	0.28%	162
2020 Q3	–	Sell	-18,000	Closed	-$323K	–	270
2020 Q2	$323K	Hold	18,000	–	–	0.29%	146
2020 Q1	$273K	Buy	18,000 +3,100	+21%	+$56.2K	0.28%	135
2019 Q4	$294K	Hold	14,900	–	–	0.16%	195
2019 Q3	$256K	Buy	+14,900	New	+$258K	0.14%	221

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Yorktown Management & Research Company's TAK Position: Q2 2023 in Review

Yorktown Management & Research Company sold out of Takeda Pharmaceutical (TAK) in Q2 2023, closing a stake of 16,000 shares — an estimated $264K sold.

Yorktown Management & Research Company first reported a position in TAK in Q3 2019 and held it in 5 quarters. The position peaked at $323K in Q2 2020. 311 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

Yorktown Management & Research Company reported no remaining Takeda Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Yorktown Management & Research Company sold 16,000 Takeda Pharmaceutical shares in Q2 2023, an estimated $264K.
Yorktown Management & Research Company first reported a position in Takeda Pharmaceutical in Q3 2019 and held it in 5 quarters.
Yorktown Management & Research Company's Takeda Pharmaceutical position peaked at $323K in Q2 2020.
311 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Yorktown Management & Research Company's 13F filing for Q2 2023, filed 28 Jul 2023.